Q2 2025 H Lundbeck A/S Earnings Call Transcript
Key Points
- H. Lundbeck AS (HLUBF) reported a 21% growth in strategic brands, with Rexulti and Vyepti showing significant increases of 28% and 56% respectively.
- The company upgraded its full-year revenue and adjusted EBITDA guidance, reflecting strong performance and positive momentum.
- H. Lundbeck AS (HLUBF) is expanding its neurospecialty position with new filings for Vyepti in Asia and advancing anti-PACAP into Phase II.
- The company has a robust pipeline with 5 to 6 mid-stage assets in Phase II or III, supporting long-term sustainable growth.
- The capital reallocation program is expected to generate EUR1.3 billion to EUR1.5 billion by 2027, funding further innovation and growth.
- The US revenue for Brintellix decreased by 6% due to the transfer of promotional responsibility to Takeda, impacting overall revenue.
- There are challenges in the regulatory approval process for the Deep Ocean trial, affecting the timeline for clinical trial site initiations.
- The PTSD AdCom vote was against frontline usage of Rexulti, indicating potential hurdles in gaining approval for new indications.
- Higher R&D costs increased by 22%, driven by the progression of Phase III programs, impacting overall profitability.
- Net financial expenses reached EUR554 million due to unfavorable currency effects and higher interest costs related to new debt.
Ladies and gentlemen, welcome to the Lundbeck A/S Financial statements for the first six months of 2025 conference call. I'm Iruna, the Chorus Call operator. (Operator Instructions) The conference is being recorded.
The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Charles Van Zyl, President and CEO. Please go ahead, sir.
/- -
Good morning, everyone, and welcome to our first half results for 2025. And I want to, at the outset, also thank you for your flexibility to join the call at relatively short notice. Of course, we are very pleased with the good news we're delivering today to you. And it's, again, in my view, a very strong validation of our focused innovator strategy. So if we go to the next slide, please.
So as part of our forward-looking statements and disclaimer, of course, what we discuss today is subject to change. Then if we could go to the next slide, please, just to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
